- Home
- SONO vs HRMY Comparison
SONO vs HRMY Comparison
Compare SONO & HRMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SONO | HRMY |
|---|---|---|
| Founded | 2002 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Consumer Electronics/Video Chains | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 1.8B |
| IPO Year | 2018 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SONO | HRMY |
|---|---|---|
| Price | $16.25 | $32.96 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 3 | 9 |
| Target Price | $19.67 | ★ $44.11 |
| AVG Volume (30 Days) | ★ 1.3M | 734.1K |
| Earning Date | 05-04-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 7.97 |
| EPS | 0.52 | ★ 0.55 |
| Revenue | ★ $1,443,276,000.00 | $868,453,000.00 |
| Revenue This Year | $5.04 | $19.75 |
| Revenue Next Year | $6.53 | $12.88 |
| P/E Ratio | ★ $30.23 | $58.36 |
| Revenue Growth | N/A | ★ 21.51 |
| 52 Week Low | $9.97 | $25.52 |
| 52 Week High | $19.82 | $40.87 |
Technical Indicators
Market Signals| Indicator | SONO | HRMY |
|---|---|---|
| Relative Strength Index (RSI) | 61.07 | 62.92 |
| Support Level | $15.83 | $31.61 |
| Resistance Level | $17.81 | $33.11 |
| Average True Range (ATR) | 0.59 | 0.90 |
| MACD | 0.06 | 0.17 |
| Stochastic Oscillator | 76.21 | 99.40 |
Price Performance
Historical ComparisonAbout SONO Sonos Inc.
Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.
About HRMY Harmony Biosciences Holdings Inc.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.